{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:22:17Z","timestamp":1791235337143,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["MU4233\/1-1"],"award-info":[{"award-number":["MU4233\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008799","name":"Foundation for Pathobiochemistry and Molecular Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008799","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jtha.2025.08.027","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:30:36Z","timestamp":1757550636000},"page":"3883-3894","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Simvastatin competitively inhibits cellular signaling of lipid-binding antiphospholipid antibodies"],"prefix":"10.1016","volume":"23","author":[{"given":"Dominika","family":"Marova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Frankenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Hollerbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Strand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Ruf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl J.","family":"Lackner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0409-7474","authenticated-orcid":false,"given":"Nadine","family":"M\u00fcller-Calleja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.08.027_bib1","doi-asserted-by":"crossref","first-page":"17103","DOI":"10.1038\/nrdp.2017.103","article-title":"Antiphospholipid syndrome","volume":"4","author":"Schreiber","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jtha.2025.08.027_bib2","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jtha.2025.08.027_bib3","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1136\/annrheumdis-2013-203622","article-title":"A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients","volume":"73","author":"Erkan","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jtha.2025.08.027_bib4","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1177\/0961203320954520","article-title":"16th international congress on antiphospholipid antibodies task force report on obstetric antiphospholipid syndrome","volume":"29","author":"de Jes\u00fas","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.jtha.2025.08.027_bib5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","article-title":"Pleiotropic effects of statins","volume":"45","author":"Liao","year":"2005","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jtha.2025.08.027_bib6","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1002\/1529-0131(200112)44:12<2870::AID-ART475>3.0.CO;2-Y","article-title":"Statins prevent endothelial cell activation induced by antiphospholipid (anti\u2013\u03b22-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype","volume":"44","author":"Meroni","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jtha.2025.08.027_bib7","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/j.1538-7836.2004.00896.x","article-title":"Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells","volume":"2","author":"Ferrara","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.08.027_bib8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s102380300015","article-title":"Different effect induced by treatment with several statins on monocyte tissue factor expression in hypercholesterolemic subjects","volume":"3","author":"Bruni","year":"2003","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.jtha.2025.08.027_bib9","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1172\/JCI58969","article-title":"Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin","volume":"122","author":"Owens","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtha.2025.08.027_bib10","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1136\/ard.2010.135525","article-title":"Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome","volume":"70","author":"L\u00f3pez-Pedrera","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jtha.2025.08.027_bib11","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1749-6632.2009.04815.x","article-title":"Statins for the treatment of antiphospholipid syndrome?","volume":"1173","author":"Jajoria","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jtha.2025.08.027_bib12","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1093\/rheumatology\/keab410","article-title":"Effect of statins on the prevention of recurrent thrombosis in thrombotic antiphospholipid syndrome","volume":"61","author":"Kwon","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jtha.2025.08.027_bib13","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1172\/JCI86957","article-title":"Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy","volume":"126","author":"Lefkou","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtha.2025.08.027_bib14","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/j.1538-7836.2004.00904.x","article-title":"New treatment option for the antiphospholipid antibody syndrome? More pleiotropic effects of the statin drugs","volume":"2","author":"Brey","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.08.027_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc0956","article-title":"Lipid presentation by the protein C receptor links coagulation with autoimmunity","volume":"371","author":"M\u00fcller-Calleja","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.jtha.2025.08.027_bib16","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1182\/bloodadvances.2018017095","article-title":"Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies","volume":"2","author":"M\u00fcller-Calleja","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.08.027_bib17","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1136\/annrheumdis-2016-210012","article-title":"Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase","volume":"76","author":"M\u00fcller-Calleja","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jtha.2025.08.027_bib18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1006\/jaut.1999.0316","article-title":"Isolation and characterization of two human monoclonal anti-phospholipid IgG from patients with autoimmune disease","volume":"13","author":"von Landenberg","year":"1999","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jtha.2025.08.027_bib19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.imbio.2010.05.001","article-title":"Structural and functional characterization of a human IgG monoclonal antiphospholipid antibody","volume":"216","author":"Prinz","year":"2011","journal-title":"Immunobiology"},{"key":"10.1016\/j.jtha.2025.08.027_bib20","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1182\/blood.2023022276","article-title":"Targeting the tissue factor coagulation initiation complex prevents antiphospholipid antibody development","volume":"143","author":"M\u00fcller-Calleja","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.08.027_bib21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1365-2125.2011.03907.x","article-title":"What is a relevant statin concentration in cell experiments claiming pleiotropic effects?","volume":"72","author":"Bj\u00f6rkhem-Bergman","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2025.08.027_bib22","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1055\/s-0037-1614977","article-title":"The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome","volume":"79","author":"Amengual","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.08.027_bib23","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1160\/TH12-06-0421","article-title":"Endosomal NADPH-oxidase is critical for induction of the tissue factor gene in monocytes and endothelial cells. Lessons from the antiphospholipid syndrome","volume":"109","author":"Prinz","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.08.027_bib24","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1182\/blood.2019001530","article-title":"Tissue factor pathway inhibitor primes monocytes for antiphospholipid antibody-induced thrombosis","volume":"134","author":"M\u00fcller-Calleja","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.08.027_bib25","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1182\/blood-2007-07-101048","article-title":"Inhibition of tissue factor signaling suppresses tumor growth","volume":"111","author":"Versteeg","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.08.027_bib26","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood-2011-01-330639","article-title":"Antiphospholipid antibodies induce translocation of TLR7 and TLR8 to the endosome in human monocytes and plasmacytoid dendritic cells","volume":"118","author":"Prinz","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.08.027_bib27","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1080\/10408363.2024.2305121","article-title":"Lipid-binding antiphospholipid antibodies: significance for pathophysiology and diagnosis of the antiphospholipid syndrome","volume":"61","author":"M\u00fcller-Calleja","year":"2024","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.jtha.2025.08.027_bib28","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/89058","article-title":"Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site","volume":"7","author":"Weitz-Schmidt","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2025.08.027_bib29","doi-asserted-by":"crossref","DOI":"10.1161\/atvb.32.suppl_1.A488","article-title":"Abstract 488: Acute fluvastatin pleiotropy is mevalonate independent","volume":"32","author":"Stein","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2025.08.027_bib30","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/carcin\/bgu019","article-title":"Atorvastatin prevents ATP-driven invasiveness via P2X7 and EHBP1 signaling in PTEN-expressing prostate cancer cells","volume":"35","author":"Ghalali","year":"2014","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jtha.2025.08.027_bib31","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1177\/0961203320950461","article-title":"16th international congress on antiphospholipid antibodies task force report on antiphospholipid syndrome treatment trends","volume":"29","author":"Cohen","year":"2020","journal-title":"Lupus"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625005525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625005525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:25:52Z","timestamp":1773332752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625005525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1538783625005525"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.08.027","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simvastatin competitively inhibits cellular signaling of lipid-binding antiphospholipid antibodies","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.08.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}